Efficiency and safety of sorafenib in treatment of renal cell carcinoma of Meta-analysis
- Author:
Hao YU
1
Author Information
- Publication Type:Journal Article
- Keywords: Meta analysis; Renal cell carcinoma; Sorafenib
- From: Chinese Pharmaceutical Journal 2014;49(5):427-430
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To systematically analyze the efficiency and safety of sorafenib in treating renal cell carcinoma. METHODS: Searched in databases of Pubmed, Medline, Cochrane library as well as domestic VIP, CNKI and Wanfang for literature ibout randomized controlled trials of sorafenib in RCC treatment, the deadline was on May 1, 2013. Evaluated the quality of these literature and made a Meta-analysis. RESULTS: Three RCT studies were included, about 1157 patients. Meta-analysis indicated that the efficiency (OR=1.88, 95% CI=1.48-2.39) and safety (OR=1.68, 95% CI=1.27-2.22) between sorafenib and other treatments, vas significant. CONCLUSION: Based on the meta-analysis, sorafenib has a significant advantage in RCC treatment to compare with other traditional scheme, but its higher incidence rate of adverse events may result to adjust the dose in the clinical application, or even feed to interrupt the treatment.
